Our pipeline of new investigational agents is aimed at targeting abnormalities in cell function in the context of pathway inhibition. Our approach is to develop specific inhibitors based on the identification of pathway signaling dependencies. This concept is at the center of the personalized medicine philosophy, in which targeted therapeutics can be tailored for patients with a defined genetic or molecular subtype of
ACM=alvocidib, cytarabine, and mitoxantrone; ACVR1=Activin A receptor, type 1; AML=acute myeloid leukemia; CDK9=cyclin dependent kinase 9.
All compounds are investigational agents, and their safety and efficacy have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.
For additional information on clinical studies, including studies that are actively recruiting, please see www.ClinicalTrials.gov.
To learn more about Tolero’s Expanded Access and Compassionate Use Policy, please visit our Guidelines.